More evidence that SGLT2i ⬇️ hyperK, this time in heart failure
Empagliflozin reduces:
- K>6.0: HR 0.62 95% CI 0.48–0.81
- Investigator reported hyperK or K binders, HR 0.82 95% CI 0.71-0.95
- Effect modified by GFR - larger in CKD
- Regardless of MRAs
1
74
208
Replies
This extends our recent collaborative meta-analysis demonstrating that SGLT2i reduces hyperkalemia (K>=6.0) in people with type 2 diabetes at high CV risk and/or with CKD, without any effect on hypokalemia
0
9
36